Request for Information Description

The objective of this Request for Information (RFI) is for BARDA program officials to better refine the requirements for oral vaccine formulations under Project NextGen using BARDA’s Rapid Response Partnership Vehicle (RRPV).

The challenges associated with oral vaccine manufacturing include maintaining antigen stability, navigating the gastrointestinal environment, and achieving scalable and cost-effective manufacturing processes.

To address these limitations, BARDA wishes to identify and advance innovative approaches for oral formulation of vaccines. BARDA envisions that advancing oral formulation could improve vaccine’s efficacy, uptake, compliance, and accessibility. The information requested from this RFI will serve as continued market research in support of a potential program under BARDA’s RRPV wherein BARDA would partner with organizations to work towards fulfilling the goals of the Project NextGen Enablers Program.

Submission Information

Respondents do not have to be a member of the Rapid Response Partnership Vehicle (RRPV) consortium to submit a response for this RFI; however, they must be a member of the consortium to respond to any future request for project proposals (RPP) for this requirement.

Please submit papers by email to [email protected] no later than the close of business on April 19, 2024.

This RFI is issued for information and planning purposes only and does not constitute a solicitation. All information received in response to the RFI that is marked as proprietary will be handled accordingly by the Government and ATI. Responses to this RFI are not considered offers and cannot be accepted by BARDA to form a binding contract.  Responders are solely responsible for all expenses associated with responding to this RFI.  All information submitted in response to this RFI shall remain with the Government and will not be returned.

Request for Information Details

Original RFI Release:

Issued: 4 March 2024

Due: 19 April 2024